SK Biopharmaceuticals Co., Ltd.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 326030.KS | 302440.KS | 005690.KS | 060590.KQ | UNC.F | SILO | |
|---|---|---|---|---|---|---|
| Market cap | 7.10T | 2.90T | 522.03B | 63.96B | 54.28B | 2.93M |
| P/E (TTM) | — | — | — | — | 25.2 | — |
| Forward P/E | — | — | — | — | — | -1.9 |
| Price/book | — | — | — | — | 4.7 | 0.3 |
| Dividend yield | — | — | 0.55% | — | 0.53% | — |
| 1-year change | −33.08% | −40.00% | −50.06% | −47.01% | +28.54% | −82.01% |
| Today | +12.27% | +7.10% | −3.76% | +2.49% | +3.11% | +3.91% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 20 min.
Latest news
All 326030.KS news ›SK Biopharmaceuticals Seeks U.S. Label Expansion for Epilepsy Drug Xcopri
Filing Targets Generalized Tonic-Clonic Seizure Patients Aged 12 and Older Company Also Pursuing Pediatric Use and Liquid Formulation SK Biopharmaceuticals (326030.KS) has begun the regulatory process to broaden the U.S. treatment scope of…
SK Biopharmaceuticals Submits Supplemental New Drug Application to U.S. FDA for Cenobamate
Nov 04, 2026, 09:52 ET - Submission supported by results from a global Phase 3 trial evaluating the efficacy and safety of cenobamate in patients with PGTC seizures- A separate sNDA also seeks to expand the existing focal-onset seizure…
SK Biopharmaceuticals seeks FDA nod to expand cenobamate to generalized seizures
Chosunbiz SK Biopharmaceuticals seeks FDA nod to expand cenobamate to generalized seizures SK Biopharmaceuticals(326030) applied to the U.S. Food and Drug Administration (FDA) for approval of a new indication for the e
SK Biopharmaceuticals Files FDA Application to Expand Xcopri Indication to Primary Generalized Tonic-Clonic Seizures, Broadening US Prescribing Base
SK Biopharmaceuticals has submitted a supplemental New Drug Application (sNDA) to the US Food and Drug Administration to expand the US indication for its epilepsy treatment Xcopri from partial-onset seizures to primary generalized…
SK Biopharmaceuticals Shares Cenobamate Lessons With U.S. Experts
Seoul Economic Daily SK Biopharmaceuticals (326030.KS) shared its experience developing and commercializing cenobamate, an epilepsy treatment, with pharmaceutical and biotechnology experts in the United States The company said on the
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- asiae.co.kr1
- en.sedaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 2 articles, not a forecast.